Brief: Adicet Bio Announces FDA Clearance Of IND Amendment To Evaluate ADI-001 In Idiopathic Inflammatory Myopathy And Stiff Person Syndrome
16/10/2024 12:36
Oct 16 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET BIO ANNOUNCES FDA CLEARANCE OF IND AMENDMENT TO
EVALUATE
ADI-001 IN IDIOPATHIC INFLAMMATORY MYOPATHY AND STIFF PERSON
SYNDROME
* ADICET BIO INC - PATIENT ENROLLMENT FOR IIM AND SPS
EXPECTED IN
Q1 2025
* ADICET BIO INC: TO REPORT INITIAL CLINICAL DATA FROM PHASE
1
STUDY IN MULTIPLE AUTOIMMUNE DISEASES IN H1 2025
Source text for Eikon: ID:nBw7tBh1na
Further company coverage: ACET.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary